Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Avmapki Fakzynja co-pack Coverage Updat…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP.PHAR.731

    Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack) coverage criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP.PHAR.731 alerts

    Get alerted when Policy CP.PHAR.731 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, prior authorization, and coverage parameters for the co-packaged combination of avutometinib and defactinib (Avmapki Fakzynja Co-Pack), primarily for KRAS‑mutated recurrent low-grade serous ovarian cancer; affects prescribers and payers reviewing initial and continuation requests.

    Policy Summary
    PayerHealth Net
    PolicyAvutometinib; Defactinib (Avmapki Fakzynja Co-Pack) coverage criteria
    Policy CodePolicy CP.PHAR.731
    Change TypeApproval duration revisedICHRA line added
    Effective DateSep 1, 2025
    Next Review DateAug 26, 2026
    Key ActionSubmit prior authorization with documentation showing diagnosis of KRAS‑mutated recurrent LGSOC, prior systemic therapy, oncologist involvement, and dosing within policy limits.
    SourceLink
    POLICY UPDATE CHANGES

    Revised initial approval duration from 6 months to 12 months.

    Added ICHRA line of business to applicable coverage.

    1FDA-approved indication
    12 moApproval duration
    ≥18 yrsMinimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Specified
    Dose limits

    Coverage Criteria

    Continuation Therapy — Covered when ALL of the following are met for Continued Therapy (Ovarian Cancer).

    Covered when ALL of the following are met for Continued Therapy (Ovarian Cancer):

    Continuation Therapy - Ovarian Cancer: 1. Member is currently receiving Avmapki Fakzynja Co-Pack via the Centene benefit, or documentation supports current receipt for a covered indication for at least 30 days; 2. Member is responding positively to therapy; 3. Avmapki Fakzynja Co-Pack is not prescribed concurrently with any other agents for LGSOC; 4. Member must use both avutometinib and defactinib, if available, unless contraindicated or clinically significant adverse effects occur; 5. If request is for a dose increase, the new dose must either: a) not exceed for the first 3 weeks of every 4-week cycle Avmapki 6.4 mg (8 capsules) per week and Fakzynja 400 mg (2 tablets) per day; OR b) be supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN; Approval duration: 12 months

    Other/Off-label — Other diagnoses/indications (alternative handling).

    Other diagnoses/indications (alternative handling):

    Other Indications: 1. If the drug label has changed within the last 6 months and the policy is not yet updated, refer to the applicable formulary/no-coverage or non-formulary policy for the relevant line of business as listed in policy (see CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16 as applicable); 2. If the requested use is not listed under section III and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business (CP.CPA.09 for commercial, HIM.PA.154 for ICHRA, CP.PMN.53 for Medicaid).

    See referenced policies for coverage determinations

    Requests for use of Avmapki Fakzynja Co-Pack for non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for ICHRA/Marketplace, and CP.PMN.53 for Medicaid).

    Use of the co‑pack for off‑label indications without adequate supporting evidence or without following the referenced off‑label use policies is not authorized (i.e., will be considered not covered). Providers seeking authorization for such uses must follow the applicable off‑label submission requirements and supply clinical documentation per those policies.

    Initial Therapy Criteria

    Continuation Therapy Criteria

    Provider Actions / Requirements

    Prior Authorization

    Prior authorization required — demonstrate all initial approval criteria

    Prior authorization is required. The request must demonstrate all Initial Approval criteria for ovarian cancer: diagnosis of low-grade serous ovarian cancer (LGSOC); prescribed by or in consultation with an oncologist; age ≥ 18 years; disease is recurrent; disease is positive for a KRAS mutation; the Avmapki Fakzynja co-pack is not prescribed concurrently with any other agents for LGSOC; the member has received prior systemic therapy (see Appendix B); the member will use avutometinib and defactinib if available unless contraindicated or intolerant; and the dose meets the policy limits or is supported by practice guidelines/peer‑reviewed literature. Approval duration for initial requests is 12 months.

    • Diagnosis: LGSOC
    • Oncologist involvement required
    • Age ≥ 18 years
    • Recurrent disease
    • KRAS mutation positive
    • No concurrent agents for LGSOC
    • Prior systemic therapy received (see Appendix B)
    • Use both agents unless contraindicated
    • Dose ≤ Avmapki 6.4 mg/week and Fakzynja 400 mg/day for first 3 weeks of each 4-week cycle OR guideline-supported dosing

    Coding and Product Availability

    Product availability / NDCNDC
    NDC not specifiedCo-packaged avumetinib 0.8 mg capsule and defactinib 200 mg tablet (product availability listed; no NDC provided in policy)
    Dose limits (first 3 weeks of each 4-week cycle)
    Avmapki (avutometinib)3.2 mg orally twice weekly (total 6.4 mg/week) during the first 3 weeks of each 4‑week cycle
    Fakzynja (defactinib)200 mg orally twice daily (total 400 mg/day) during the first 3 weeks of each 4‑week cycle
    Cycle timingDose limits apply to the first 3 weeks of every 4‑week cycle

    Quantity and Dosing Limits

    Avmapki (avutometinib)
    Recommended regimen3.2 mg PO twice weekly (Day 1 and Day 4) — total 6.4 mg/week for the first 3 weeks of each 4‑week cycle
    Use requirementUse as part of Avmapki Fakzynja Co‑Pack; member must use avutometinib if available unless contraindicated or intolerant
    ContextDosing recommendation applies until disease progression or unacceptable toxicity
    Fakzynja (defactinib)
    Recommended regimen200 mg PO twice daily (total 400 mg/day) for the first 3 weeks of each 4‑week cycle
    Use requirementUse as part of Avmapki Fakzynja Co‑Pack; member must use defactinib if available unless contraindicated or intolerant

    Step Therapy / Prior Systemic Therapy

    StepRequirement
    1Member must have received prior systemic therapy (see Appendix B for therapeutic alternatives); specific number or regimen of prior therapies is not mandated.
    2Avmapki Fakzynja Co-Pack is not to be prescribed concurrently with any other agents for low‑grade serous ovarian cancer (LGSOC).
    3Use of the co‑pack must follow availability guidance: member should use avutometinib and defactinib, if available, unless contraindicated or intolerant.
    4Prescribed regimen must be FDA‑approved or recommended by NCCN; dosing limits in Appendix/criteria apply (see dose limits for first 3 weeks of each 4‑week cycle).

    Definitions

    low-grade serous ovarian cancer
    TermLow‑grade serous ovarian cancer (LGSOC)
    AbbreviationLGSOC = low‑grade serous ovarian cancer
    Policy contextDiagnosis of LGSOC is required for initial approval of Avmapki Fakzynja Co‑Pack for the covered indication

    Background

    Avmapki Fakzynja Co‑Pack combines two kinase inhibitors, avutometinib and defactinib. The combination is FDA‑approved under accelerated approval for adult patients with KRAS‑mutated recurrent low‑grade serous ovarian cancer (LGSOC) after prior systemic therapy; continued approval may depend on confirmatory trial data. For requests outside the FDA‑approved indication, see the off‑label use policies referenced in this policy.

    Site of Care

    Note

    Site of care — infusion center not specified

    Site of care for administration is not specified in the policy.

    • No requirement or restriction listed for use in an infusion center

    Revision History

    2026-08-26annual review / revisionLatest

    3Q 2026 annual review: revised initial approval duration from 6 months to 12 months and added ICHRA line of business; references reviewed and updated.

    2025-05-15policy creation

    Policy created (initial version).

    2026-04-15review
    Policy Summary
    PayerHealth Net
    PolicyAvutometinib; Defactinib (Avmapki Fakzynja Co-Pack) coverage criteria
    Policy CodePolicy CP.PHAR.731
    Change TypeApproval duration revisedICHRA line added
    Effective DateSep 1, 2025
    Next Review DateAug 26, 2026
    Key ActionSubmit prior authorization with documentation showing diagnosis of KRAS‑mutated recurrent LGSOC, prior systemic therapy, oncologist involvement, and dosing within policy limits.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaProvider Actions / RequirementsCoding and Product AvailabilityQuantity and Dosing LimitsStep Therapy / Prior Systemic TherapyDefinitionsBackgroundSite of CareRevision History
    Step Therapy

    Step/sequence expectations — no concurrent agents; prior systemic therapy required

    The policy requires the co-pack to be used without concurrent agents for LGSOC and that the member has received prior systemic therapy (see Appendix B for therapeutic alternatives); specific step failures are not enumerated beyond the prior systemic therapy requirement.

    • Co-pack must not be prescribed concurrently with any other agents for LGSOC
    • Member must have received prior systemic therapy (see Appendix B)
    Documentation Required

    Required clinical documentation — submit office notes and test results

    Provider must submit supporting clinical documentation such as office chart notes, laboratory results, or other clinical information to show the member meets all approval criteria.

    • Include documentation confirming diagnosis, KRAS mutation status, prior systemic therapy, oncologist involvement, and dosing rationale or supporting literature if applicable
    Denial Risk

    Documentation and indication mismatch — risk of denial if criteria not documented

    Requests that do not include documentation showing the member meets all approval criteria (for example: LGSOC diagnosis, KRAS mutation positivity, prior systemic therapy) or that are for non‑covered indications without off‑label policy support may be denied.

    • Missing evidence of required diagnosis, mutation status, or prior therapy risks denial
    • Requests for non‑FDA‑approved indications without sufficient off‑label documentation per referenced off‑label policies may be not authorized
    ContextDosing recommendation applies until disease progression or unacceptable toxicity

    References reviewed and updated during 3Q 2026 review cycle (administrative update recorded).